At close: December 13 at 4:00:01 PM EST
After hours: 7:59:27 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 4 | 4 |
| Avg. Estimate | -0.23 | -0.25 | -1 | -0.84 |
| Low Estimate | -0.26 | -0.26 | -1.04 | -1 |
| High Estimate | -0.2 | -0.24 | -0.9 | -0.45 |
| Year Ago EPS | -0.35 | -0.25 | -1.65 | -1 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 1 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.37 | -0.38 | -0.31 | -0.25 |
| EPS Actual | -0.35 | -0.25 | -0.26 | -0.25 |
| Difference | 0.02 | 0.13 | 0.05 | 0 |
| Surprise % | 6.25% | 33.63% | 16.13% | 0.00% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.23 | -0.25 | -1 | -0.84 |
| 7 Days Ago | -0.23 | -0.25 | -1 | -0.86 |
| 30 Days Ago | -0.23 | -0.25 | -1 | -0.86 |
| 60 Days Ago | -0.22 | -0.25 | -0.95 | -0.99 |
| 90 Days Ago | -0.24 | -0.24 | -1 | -0.94 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | 1 |
| Up Last 30 Days | 1 | 1 | 2 | 1 |
| Down Last 7 Days | -- | 1 | -- | -- |
| Down Last 30 Days | -- | 1 | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| RVPH | 34.29% | 1.33% | 39.70% | 15.33% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Maintains | D. Boral Capital: Buy to Buy | 11/14/2024 |
| Maintains | D. Boral Capital: Buy to Buy | 11/13/2024 |
| Initiated | EF Hutton: Buy | 9/23/2024 |
| Reiterates | Benchmark: Speculative Buy to Speculative Buy | 8/26/2024 |
| Downgrade | Maxim Group: Buy to Hold | 8/16/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/11/2024 |
Related Tickers
ALGS Aligos Therapeutics, Inc.
34.07
+2.90%
BIVI BioVie Inc.
2.6400
+1.93%
CLDI Calidi Biotherapeutics, Inc.
1.8500
-1.07%
CRDF Cardiff Oncology, Inc.
3.9200
+19.88%
CMRX Chimerix, Inc.
2.9500
+0.34%
PCSA Processa Pharmaceuticals, Inc.
1.1100
-11.20%
TARA Protara Therapeutics, Inc.
5.98
-4.32%
QURE uniQure N.V.
15.40
+2.26%
CDIO Cardio Diagnostics Holdings, Inc.
1.2600
+5.00%
SLXN Silexion Therapeutics Corp
3.5200
+5.39%